Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of enpatoran for active cutaneous manifestations of lupus erythematosus
MOH_2026-05-12_015818Phase 3Not yet recruiting
- Sponsor
- Merck KGaA
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) comparing enpatoran with placebo (2 arms). Primary endpoint: CLASI 70 response at Week 24. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
enpatoran
03
Conditions
lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2026-05-12_015818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-12_015818.